

BioGaia invests further in MetaboGen

On April 6, 2018, BioGaia became the majority shareholder in MetaboGen with a 62 percent stake. BioGaia has now, after the set milestones have been achieved, decided to further extend its holding, resulting in a shareholding of 92 percent of the shares in MetaboGen. The acquisition value of the additional 30 percent amounts to approximately SEK 27.8 million.

BioGaia will also acquire the remaining eight percent in the company within a three-year period. The additional purchase price can amount to a maximum of SEK 12 million depending on how many milestones are achieved.

BioGaia's previous investments in MetaboGen

In December 2014 BioGaia reported its decision to invest SEK 12 million in MetaboGen. The investment should be made over a two-year period and included conditions for agreed milestones. The first investment of SEK four million was carried out in December 2014, the second in December 2015 and the third investment in December 2016. BioGaia thereafter owned 36 percent of the share capital of MetaboGen. In April 2018 a further SEK 11.7 million were invested in the company and BioGaia became the majority shareholder in MetaboGen with 62 percent of the shares.

"MetaboGen has quickly achieved the set milestones, which means that we will get a more extensive and even closer cooperation with the University of Gothenburg and Chalmers University of Technology within the hot microbiome area. We are looking forward to these collaborations with confidence," says Peter Rothschild, Chairman of the Board, BioGaia.

About MetaboGen

MetaboGen was founded in 2011 by Professor Fredrik Bäckhed at the University of Gothenburg and Professor Jens B Nielsen at Chalmers University of Technology, together with GU Ventures, which commercializes research findings and develops companies related to the University of Gothenburg.

In addition to assignments for BioGaia, MetaboGen has a collaboration with the pharmaceutical company Ferring and holds a number of patents and patent applications in the microbiome field. The company has a laboratory in Gothenburg where development of new probiotic strains takes place. Read more on metabogen.se.

For additional information please contact

Peter Rothschild, Chairman of the Board, BioGaia, telephone: +46 708 30 65 40
Sebastian Schröder, Acting Managing Director, BioGaia, telephone: +46 8 555 293 00

Latest press releases from BioGaia

2018-06-26	Now published: <i>Lactobacillus reuteri</i> reduced bone loss in older women
2018-06-20	BioGaia appoints new Managing Director
2018-05-23	Management changes at BioGaia

This information is information that BioGaia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the Chairman of the Board, at 10.00 AM CET on July 4 2018.

BioGaia is an innovative Swedish healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are sold through local distribution partners in 100 countries worldwide. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaia.com

